Legal Representation
Attorney
Spencer Wolff Esquire
USPTO Deadlines
Application History
21 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 12, 2025 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| May 12, 2025 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Oct 8, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Aug 13, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 13, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jul 24, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 10, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 10, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 10, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 10, 2024 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jan 18, 2024 | NREV | E | NOTICE OF REVIVAL - E-MAILED | Loading... |
| Jan 17, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jan 17, 2024 | NREV | E | NOTICE OF REVIVAL - E-MAILED | Loading... |
| Jan 17, 2024 | PETG | O | PETITION TO REVIVE-GRANTED | Loading... |
| Jan 17, 2024 | PROA | I | TEAS PETITION TO REVIVE RECEIVED | Loading... |
| Oct 10, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 10, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 10, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Oct 4, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| May 31, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| May 5, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
pharmaceutical preparations for the treatment of opioid dependence, benzodiazepine dependence, anaphalytic shock, seizures, hypoglycemia, neurodegenerative disorders, allergies, blood pressure, acute chest pain, mastocytosis disease, pain management, anxiety, post-traumatic stress disorder, sleep disorders, hypercalcaemia, osteoporosis, migraines, hormone replacement therapy side effects, smoking cessation, nausea, motion sickness, heartburn, indigestion, acid reflux, hemophiliac bleeding, urinary incontinence, mood disorders, vitamin deficiencies, low phosphate levels, diarrhea, asthma, chronic obstructive pulmonary disease, endometriosis, and early puberty
Class 042
scientific research and development; medical research; pharmaceutical research and development
Class 044
medical and healthcare information services
Classification
International Classes
005
042
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMA"